BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates
View/ Open
Author
Kiguchi, Norikazu
Ding, Huiping
Cami-Kobeci, Gerta
Sukhtankar, Devki D.
Czoty, Paul W.
DeLoid, Heather B.
Hsu, Fang Chi
Toll, Lawrence
Husbands, Stephen M.
Ko, Mei Chuan
Attention
2299/21352
Abstract
Background: The marked increase in mis-use of prescription opioids has greatly affected our society. One potential solution is to develop improved analgesics which have agonist action at both mu opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptors. BU10038 is a recently identified bifunctional MOP/NOP partial agonist. The aim of this study was to determine the functional profile of systemic or spinal delivery of BU10038 in primates after acute and chronic administration. Methods: A series of behavioural and physiological assays have been established specifically to reflect the therapeutic (analgesia) and side-effects (abuse potential, respiratory depression, itch, physical dependence, and tolerance) of opioid analgesics in rhesus monkeys. Results: After systemic administration, BU10038 (0.001–0.01 mg kg −1 ) dose-dependently produced long-lasting antinociceptive and antihypersensitive effects. Unlike the MOP agonist oxycodone, BU10038 lacked reinforcing effects (i.e. little or no abuse liability), and BU10038 did not compromise the physiological functions of primates including respiration, cardiovascular activities, and body temperature at antinociceptive doses and a 10–30-fold higher dose (0.01–0.1 mg kg −1 ). After intrathecal administration, BU10038 (3 μg) exerted morphine-comparable antinociception and antihypersensitivity without itch scratching responses. Unlike morphine, BU10038 did not cause the development of physical dependence and tolerance after repeated and chronic administration. Conclusions: These in vivo findings demonstrate the translational potential of bifunctional MOP/NOP receptor agonists such as BU10038 as a safe, non-addictive analgesic with fewer side-effects in primates. This study strongly supports that bifunctional MOP/NOP agonists may provide improved analgesics and an alternative solution for the ongoing prescription opioid crisis.
Publication date
2019-06-01Published in
British Journal of AnaesthesiaPublished version
https://doi.org/10.1016/j.bja.2018.10.065Other links
http://hdl.handle.net/2299/21352Metadata
Show full item recordRelated items
Showing items related by title, author, creator and subject.
-
Designer Benzodiazepines’ Activity on Opioid Receptors: A Docking Study
Catalani, Valeria; Botha, Michelle; Corkery, John Martin; Guirguis, Amira; Vento, Alessandro; Schifano, Fabrizio (2022-09-22)BACKGROUND: Previous studies have reported that benzodiazepines (BZDs) seem to enhance euphoric and reinforcing properties of opioids in opioid users so that a direct effect on opioid receptors has been postulated, together ... -
Synthesis, biological evaluation, and SAR studies of 14β-phenylacetyl substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones derivatives : Ligands with mixed NOP and opioid receptor profile
Kumar, Vinod; Polgar, Willma E.; Cami-Kobeci, Gerta; Thomas, Mark P.; Khroyan, Taline V.; Toll, Lawrence; Husbands, Stephen M. (2018-09-19)A series of 14β-acyl substituted 17-cyclopropylmethyl-7,8-dihydronoroxymorphinone compounds has been synthesized and evaluated for affinity and efficacy for mu (MOP), kappa (KOP), and delta (DOP) opioid receptors and ... -
Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment
Specka, Michael; Kuhlmann, Thomas; Bonnet, Udo; Sawazki, Jürgen; Schaaf, Luzia; Kühnhold, Stefan; Steinert, Renate; Grigoleit, Torsten; Eich, Helmut; Zeiske, Benita; Niedersteberg, Antje; Steiner, Katharina; Schifano, Fabrizio; Scherbaum, Norbert (2022-06-01)Introduction: Over the last decade, the use of New/Novel Synthetic Opioids (NSO) has emerged as an increasing problem, and especially so in the USA. However, only little is known about the prevalence and history of NSO use ...